Isotechnika Pharma Inc IPHAF

RE: I'm out

[redrill]

Is the glass half full or is it half empty?? 
Obviously for MacB it is half empty or even worse......
Here is another take on the issue where I see the glass as half full......
\
FDA has cancelled the meeting because they just don't see the need at this point.  The "issues" to be resolved involve other applications for the drug as most of the submitted data comes from either psorasis trials or from transplant trials.   It has been awhile since those were completed and I do believe I read that transplant patients had the option of staying on the drug if they so chose.  that would mean there is a fair timeline associated with some patients and if the results are good(great) then PERHAPS the issues relate to psoriasis or transplant and the FDA is actually planning on allowing broader use of the drug than just uvetis.  They cancelled the june 28th meeting cause it wasn't nescesary for uvetis........Hey, if your gonna speculate why not give equal time to the positive side of things!!!!